Skip to main content
. 2024 Jan 11;14:1341708. doi: 10.3389/fimmu.2023.1341708

Figure 1.

Figure 1

Overall probability of drug survival throughout the study period for interleukin (IL-)12/23, IL-17 and IL-23 inhibitors. Data are presented as probability with 95% C.I. (Confidence Interval).